Tuesday, 17 November 2026European Markets

DMS IMAGING Stock Slides By 28% In The Last 21 Sessions

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Loading stream...

(VIANEWS) - Shares of DMS IMAGING (BEL 20: DMSIM.BR) slid by a staggering 28.91% in 21 sessions from $0.04 to $0.03 at 13:04 EST on Tuesday, following the last session's upward trend. BEL 20 is sliding 0.4% to $3,873.24, after two successive sessions in a row of losses.

About DMS IMAGING

DMS Imaging SA, a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen. The company is also developing hdm-ASIT+ for the treatment of house dust mite allergy; and pnt-ASIT+ for the treatment of peanut allergy. The company was formerly known as ASIT Biotech S.A. and changed its name to DMS Imaging SA in February 2022. DMS Imaging SA was incorporated in 1997 and is based in Liege, Belgium.

More news about DMS IMAGING (DMSIM.BR).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

  1. Published before we listed source documents with each article.
  2. Published 7 Feb 2023
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›